Table 2 shows the therapeutic prospect of Targeting HNRNPA2B1 in diseases. The broad-spectrum antiviral drug PAC5, for example, binds to a pocket near the Asp49 RNA recognition motif (RRM1) of HNRNPA2B1, inducing its translocation into the cytoplasm and activating the TBK1-IRF3 pathway to exert antiviral effects (114). In the tumor microenvironment, the natural compound Sanggenol-O and its synthetic derivative MO-460 inhibit hypoxia-inducible factor 1 alpha (HIF-1α) expression via HNRNPA2B1, thereby triggering apoptosis (115), highlighting their potential as anticancer agents. This evidence concerns the gene HNRNPA2B1 and neoplasm.